Test Details
Methodology
HLA results are obtained using Next Generation Sequencing (NGS). Supplemental procedures based on Sanger sequence based typing (SBT) may be used as needed to obtain the required resolution.
|
HLA results are obtained using Next Generation Sequencing (NGS). Supplemental procedures based on Sanger sequence based typing (SBT) may be used as needed to obtain the required resolution. |
Result Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Use
Allopurinol associated SCAR (severe cutaneous adverse drug reaction) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) has been shown to be associated with the human leukocyte antigen (HLA) B*58:01 of the major histocompatibility complex (MHC). The MHC family of genes codes for a highly variable set of cell surface glycoproteins (HLAs) that play a critical role in presenting antigens to T-cell receptors to elicit an immune response. The presence of the HLA B*58:01 allele increases the susceptibility to allopurinol SCAR in several populations studied.
Special Instructions
If you have questions, please telephone 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting.
This test was developed Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting. |
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting. |
References
Specimen Requirements
Specimen
Whole blood or buccal swabs
Volume
7 mL whole blood or 4 buccal swabs
Minimum Volume
7 mL whole blood or four (4) buccal swabs
Container
Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal kit, please telephone 800-533-1037.
Storage Instructions
Maintain whole blood at room temperature or refrigerate. Keep buccal swabs dry and at room temperature.
Causes for Rejection
Hemolysis; clotted specimen; insufficient volume of DNA
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 167351 | HLA B*58:01 | 13299-3 | 167343 | HLA-B | 13299-3 | |
| 167351 | HLA B*58:01 | 13299-3 | 167345 | HLA-B | 13299-3 | |
| 167351 | HLA B*58:01 | 13299-3 | 167384 | HLA Methodology | 49549-9 | |
| Order Code | 167351 | |||||
| Order Code Name | HLA B*58:01 | |||||
| Order Loinc | 13299-3 | |||||
| Result Code | 167343 | |||||
| Result Code Name | HLA-B | |||||
| UofM | ||||||
| Result LOINC | 13299-3 | |||||
| Order Code | 167351 | |||||
| Order Code Name | HLA B*58:01 | |||||
| Order Loinc | 13299-3 | |||||
| Result Code | 167345 | |||||
| Result Code Name | HLA-B | |||||
| UofM | ||||||
| Result LOINC | 13299-3 | |||||
| Order Code | 167351 | |||||
| Order Code Name | HLA B*58:01 | |||||
| Order Loinc | 13299-3 | |||||
| Result Code | 167384 | |||||
| Result Code Name | HLA Methodology | |||||
| UofM | ||||||
| Result LOINC | 49549-9 |